Related Experiment Video
Updated: Jul 29, 2025
07:06
Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
Published on: December 8, 2014
27.2K
Treating Clostridioides difficile: Could Microbiota-based Live Biotherapeutic Products Provide the Answer?
Sandhya Nagarakanti1, Robert Orenstein1
1Division of Infectious Diseases, Mayo Clinic Arizona, Phoenix, AZ, USA.
Infection and Drug Resistance
|May 26, 2023
Summary
Live biotherapeutic products (LBPs) show promise for treating recurrent Clostridioides difficile infection (CDI). Further research is needed to optimize LBPs for safe and effective clinical use as an alternative to fecal microbiota transplantation (FMT).
Area of Science:
- Microbiology
- Gastroenterology
- Pharmacology
Background:
- Clostridioides difficile infection (CDI) presents significant healthcare challenges due to treatment limitations and high recurrence.
- Existing antibiotic therapies for CDI negatively impact the gut microbiome, increasing the risk of recurrent infections.
- Fecal microbiota transplantation (FMT) offers improved outcomes for recurrent CDI but faces safety and standardization concerns.
Purpose of the Study:
- To review the potential of microbiota-based live biotherapeutic products (LBPs) as a safe and effective alternative therapy for CDI.
- To explore the emerging role of LBPs in managing conditions associated with colonic microbiota disruption.
Main Methods:
- Literature review of preclinical and early clinical studies on LBPs for CDI treatment.
- Analysis of current therapeutic strategies and their limitations in managing CDI.
- Exploration of the safety, efficacy, and standardization of LBPs.
Main Results:
- Preclinical and early clinical studies indicate promising results for LBPs in treating CDI.
- LBPs represent a potential alternative to FMT, addressing some of its safety and standardization issues.
- Further investigation is required to establish optimal LBP composition and dosage.
Conclusions:
- Live biotherapeutic products (LBPs) hold significant promise as a novel therapeutic approach for Clostridioides difficile infection (CDI).
- LBPs may offer a safer and more standardized alternative to fecal microbiota transplantation (FMT) for recurrent CDI.
- Additional research is crucial to confirm the safety, efficacy, and optimal use of LBPs in clinical practice and other microbiota-related disorders.
Related Concept Videos
01:29Microorganisms in Medicine and Therapeutics
77
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
77
01:28Biological Methods for Microbial Control
145
Biological agents offer an effective means of controlling microbial growth by leveraging natural processes like predation, competition, and the secretion of antimicrobial substances.Predatory bacteria such as Bdellovibrio species target and kill pathogens like Salmonella and E. coli. They are widely used in poultry farms to control infections. Myxococcus species help combat plant-pathogenic fungi. These naturally occurring predators serve as eco-friendly alternatives to chemical pesticides and...
145
01:18Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
167
Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
167
01:17Drugs for Treatment of Diarrhea-Predominant IBS
224
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
224
01:29Bacterial Flora of the Large Intestine
537
The gut microbiome is formed by a vast and diverse community of bacteria that colonizes our large intestine. These bacteria start residing in the gut from birth and continue diversifying throughout life, influenced by factors such as diet, lifestyle, and stress. The gut bacterial community also includes bacteria from food and those that enter the colon through the anus.
The normal gut flora of the colon plays a critical role in generating essential vitamins such as vitamins K, B5, and B7.
The normal gut flora of the colon plays a critical role in generating essential vitamins such as vitamins K, B5, and B7.
537